Jeffrey King, MD
Cardiovascular Disease · Grand Island, NENPI 1144228966
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,858 of the $4,085 with a category attached, or 70.0%. 30 manufacturers reported payments, led by Abbott at 37.1% of the total. Reporting peaked in 2023 at $2,090 and has fallen 78.2% since, to $455 in 2025.
Across 153 payments — averaging $26.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Boston Scientific$409
- Novartis$269
- Johnson & Johnson$247
- Pfizer$177
- Musculoskeletal Transplant Foundation Inc.$156
- plus $1K from 24 others
What the payments were for
- Travel & lodging$1,22730%
- Food & beverage$2,85870%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 15 | $1,514 |
| Boston Scientific | 28 | $409 |
| Novartis | 16 | $269 |
| Johnson & Johnson | 14 | $247 |
| Pfizer | 12 | $177 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $156 |
| Merck | 10 | $146 |
| AstraZeneca | 11 | $144 |
| Boehringer Ingelheim | 6 | $102 |
| United Therapeutics Corporation | 2 | $95 |
| Amgen | 6 | $88 |
| Bridgebio Pharma, Inc. | 3 | $83 |
| Sanofi-aventis U.S. LLC | 5 | $80 |
| E.r. Squibb & Sons, L.L.C. | 2 | $76 |
| Medtronic(2 entities) | 3 | $72 |
| Lexicon Pharmaceuticals, Inc. | 3 | $63 |
| Itamar Medical Inc | 1 | $44 |
| Impulse Dynamics (USA) Inc. | 1 | $38 |
| Abiomed | 1 | $37 |
| Gilead | 2 | $34 |
| Actelion Pharmaceuticals US, Inc. | 1 | $31 |
| Regeneron Healthcare Solutions, Inc. | 2 | $31 |
| Heartflow, Inc. | 1 | $27 |
| Portola Pharmaceuticals, LLC | 1 | $25 |
| AbbVie | 1 | $22 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $20 |
| Lundbeck LLC | 1 | $15 |
| Irhythm Technologies, Inc. | 1 | $14 |
| Bayer | 1 | $14 |
| Vifor Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CARDIOMEMS$1,218
How this compares
$4,085 in reported general payments places this provider in the 65th percentile of 97 cardiovascular disease providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 346 | $260,780 |
| XareltoRivaroxaban | 239 | $213,504 |
| EntrestoSacubitril/Valsartan | 111 | $80,213 |
| Repatha SureclickEvolocumab | 55 | $35,153 |
| Praluent PenAlirocumab | 17 | $11,034 |
| BrilintaTicagrelor | 16 | $10,654 |
| Flecainide Acetate | 301 | $10,050 |
| JardianceEmpagliflozin | 12 | $9,734 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 146 | $5,420 |
| Potassium Chloride | 226 | $4,712 |
| Metoprolol Succinate | 269 | $4,095 |
| Digoxin | 13 | $3,408 |
| Carvedilol | 481 | $3,374 |
| SotalolSotalol Hcl | 150 | $3,062 |
| Atorvastatin Calcium | 262 | $3,022 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $177 | $260,780346 claims |
| Johnson & JohnsonXarelto | $247 | $213,504239 claims |
| NovartisEntresto | $269 | $80,213111 claims |
| AstraZenecaBrilinta | $144 | $10,65416 claims |
| Boehringer IngelheimJardiance | $102 | $9,73412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 97 cardiovascular disease providers in Nebraska.
Other cardiovascular disease in Grand Island
- Ronald ZoltyOmaha$945K
- Robert PercellLincoln$918K
- Steven KruegerLincoln$388K
- Jeffrey CarstensOmaha$124K
- Keith MillerLincoln$86K
- John HenryOmaha$79K
- Joseph ThibodeauOmaha$75K
- Qais RadaidehOmaha$50K
- Wynn HunterLincoln$46K
- Edward OlearyOmaha$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.